博雅生物(300294)_个股概要_股票价格_最新资讯_行情走势_历史数据 - 老虎社区

300294 博雅生物

交易中 12-18 14:10:45

{"stockData":{"symbol":"300294","market":"SZ","secType":"STK","nameCN":"博雅生物","latestPrice":22.84,"timestamp":1766038245000,"preClose":22.9,"halted":0,"volume":1574395,"delay":0,"changeRate":-0.0026,"floatShares":504000000,"shares":504000000,"eps":0.649,"marketStatus":"交易中","change":-0.06,"latestTime":"12-18 14:10:45","open":22.83,"high":22.9,"low":22.75,"amount":35939700,"amplitude":0.0066,"askPrice":22.84,"askSize":17,"bidPrice":22.83,"bidSize":177,"shortable":0,"etf":0,"ttmEps":0.649,"tradingStatus":2,"nextMarketStatus":{"tag":"收盘","tradingStatus":0,"beginTime":1766041200000},"marketStatusCode":2,"adr":0,"adjPreClose":22.9,"symbolType":"stock","openAndCloseTimeList":[[1766021400000,1766028600000],[1766034000000,1766041200000]],"highLimit":25.19,"lowLimit":20.61,"ibTradeSell":false,"ibTradeBuySell":false,"totalEquity":504248738,"isCdr":false,"pbRate":1.51,"roa":"--","peRate":35.192604,"roe":"4.5%","epsLYR":0.79,"committee":0.818744,"marketValue":11517000000,"turnoverRate":0.0031,"status":1,"floatMarketCap":11517000000},"requestUrl":"/m/hq/s/300294/tweets","defaultTab":"tweets","newsList":[{"id":"2592990391","title":"博雅生物：聚焦血液制品发展战略","url":"https://stock-news.laohu8.com/highlight/detail?id=2592990391","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2592990391?lang=zh_cn&edition=full","pubTime":"2025-12-17 20:51","pubTimestamp":1765975894,"startTime":"0","endTime":"0","summary":"证券之星消息，博雅生物12月16日在投资者关系平台上答复投资者关心的问题。从十四五华润控股博雅生物以来，几年下来博雅生物连年下跌，连续几年收入及利润不增反减，是否是公司空降的管理层能力方面不行不能带领公司发展壮大？华润控股博雅生物已久，是否考虑变更股票简称带来品牌效益？","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025121700036614.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["300294","BK0197","BK0046","BK0239"],"gpt_icon":0},{"id":"2591168983","title":"博雅生物：股东高特佳集团质押0.19%公司股份","url":"https://stock-news.laohu8.com/highlight/detail?id=2591168983","media":"新京报","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2591168983?lang=zh_cn&edition=full","pubTime":"2025-12-16 18:24","pubTimestamp":1765880640,"startTime":"0","endTime":"0","summary":"新京报贝壳财经讯 12月16日，博雅生物公告，股东深圳市高特佳创业投资集团有限公司于2025年12月12日将其持有公司的45万股无限售条件流通股解除质押，占公司总股本的0.09%。同日，融华投资将其持有的95万股无限售条件流通股质押给厦门国际银行股份有限公司珠海分行进行融资，占公司总股本的0.19%。","market":"us","thumbnail":"https://media.bjnews.com.cn/cover/2025/12/16/5665059736274411906.jpeg?x-oss-process=image/resize,m_lfit,w_365","type":0,"news_type":0,"thumbnails":["https://media.bjnews.com.cn/cover/2025/12/16/5665059736274411906.jpeg?x-oss-process=image/resize,m_lfit,w_365"],"rights":{"source":"highlight_bjnews","url":"https://www.bjnews.com.cn/detail/1765879839129444.html","rn_cache_url":null,"customStyle":"handleCustomStyle(customStyle, ThemeStyle, getFont(fontSize))","selectors":"#main .nleft","filters":".ntit, .attitude","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.bjnews.com.cn/detail/1765879839129444.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"highlight_bjnews","symbols":["BK0239","300294","BK0046","BK0197"],"gpt_icon":0},{"id":"2590098615","title":"博雅生物：控股股东及董监高无减持计划","url":"https://stock-news.laohu8.com/highlight/detail?id=2590098615","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2590098615?lang=zh_cn&edition=full","pubTime":"2025-12-12 20:51","pubTimestamp":1765543897,"startTime":"0","endTime":"0","summary":"证券之星消息，博雅生物12月11日在投资者关系平台上答复投资者关心的问题。请问十大股东及董高监有减持动作及计划吗？截至目前，公司控股股东及董监高并无减持计划。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025121200037972.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0197","300294","BK0239","BK0046"],"gpt_icon":0},{"id":"2590595396","title":"博雅生物：2025年12月10日股东人数为30,129户","url":"https://stock-news.laohu8.com/highlight/detail?id=2590595396","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2590595396?lang=zh_cn&edition=full","pubTime":"2025-12-11 16:27","pubTimestamp":1765441670,"startTime":"0","endTime":"0","summary":"证券之星消息，博雅生物(300294)12月11日在投资者关系平台上答复投资者关心的问题。投资者提问：请问截止到今天（12.10日）股东人数是多少，谢谢！博雅生物回复：您好，感谢您对本公司的关注。公司2025年12月10日含信用账户合并名册的股东人数为30,129户。以上内容为证券之星据公开信息整理，由AI算法生成（网信算备310104345710301240019号），不构成投资建议。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025121100023487.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0197","BK0239","BK0046","300294"],"gpt_icon":0},{"id":"2588874790","title":"博雅生物：静注人免疫球蛋白具免疫调节作用","url":"https://stock-news.laohu8.com/highlight/detail?id=2588874790","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2588874790?lang=zh_cn&edition=full","pubTime":"2025-12-02 15:18","pubTimestamp":1764659906,"startTime":"0","endTime":"0","summary":"证券之星消息，博雅生物12月02日在投资者关系平台上答复投资者关心的问题。公司生产的免疫球蛋白类产品多用于免疫性疾病治疗，传染性疾病被动免疫和治疗等。其中静注人免疫球蛋白主要用于原发性免疫球蛋白缺乏症、继发性免疫球蛋白缺陷病、自身免疫性疾病。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025120200017065.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0239","BK0046","300294","BK0197"],"gpt_icon":0},{"id":"2588723640","title":"博雅生物：2025年11月28日股东人数为29,994户","url":"https://stock-news.laohu8.com/highlight/detail?id=2588723640","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2588723640?lang=zh_cn&edition=full","pubTime":"2025-12-01 17:21","pubTimestamp":1764580880,"startTime":"0","endTime":"0","summary":"证券之星消息，博雅生物(300294)12月01日在投资者关系平台上答复投资者关心的问题。投资者提问：请问截止到本月月底（11.30），公司股东人数是多少？谢谢！博雅生物回复：您好，感谢您对本公司的关注。公司2025年11月28日含信用账户合并名册的股东人数为29,994户。以上内容为证券之星据公开信息整理，由AI算法生成（网信算备310104345710301240019号），不构成投资建议。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025120100021490.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0046","300294","BK0197","BK0239"],"gpt_icon":0},{"id":"2586105738","title":"博雅生物（300294）披露选举第八届董事会职工代表董事，11月28日股价下跌0.38%","url":"https://stock-news.laohu8.com/highlight/detail?id=2586105738","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2586105738?lang=zh_cn&edition=full","pubTime":"2025-11-28 22:16","pubTimestamp":1764339400,"startTime":"0","endTime":"0","summary":"公司近日发布公告称，华润博雅生物制药集团股份有限公司于2025年11月28日召开职工代表大会，选举李瑛女士为公司第八届董事会职工代表董事，任期至第八届董事会任期届满。李瑛女士现任公司财务管理部总经理，1986年出生，本科学历，无境外永久居留权，未持有公司股份，未受过相关处罚，符合董事任职资格。本次选举后，公司董事会中兼任高级管理人员及职工代表董事人数未超过董事总数的二分之一。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025112800039881.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0197","BK0046","BK0239","300294"],"gpt_icon":0},{"id":"2586268269","title":"博雅生物（300294）披露召开2025年第三次临时股东会通知，11月26日股价下跌0.62%","url":"https://stock-news.laohu8.com/highlight/detail?id=2586268269","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2586268269?lang=zh_cn&edition=full","pubTime":"2025-11-26 22:22","pubTimestamp":1764166947,"startTime":"0","endTime":"0","summary":"截至2025年11月26日收盘，博雅生物报收于23.85元，较前一交易日下跌0.62%，最新总市值为120.26亿元。该股当日开盘24.0元，最高24.12元，最低23.85元，成交额达8279.02万元，换手率为0.68%。公司近日发布公告称，华润博雅生物制药集团股份有限公司将于2025年12月12日召开2025年第三次临时股东会，会议由公司董事会召集，现场会议地点为江西省抚州市高新技术产业园开发区惠泉路333号。股权登记日为2025年12月5日，网络投票通过深圳证券交易所系统进行。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025112600038964.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0197","BK0239","BK0046","300294"],"gpt_icon":0},{"id":"2586641255","title":"博雅生物(300294.SZ)取得破伤风人免疫球蛋白药品注册证书","url":"https://stock-news.laohu8.com/highlight/detail?id=2586641255","media":"智通财经","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2586641255?lang=zh_cn&edition=full","pubTime":"2025-11-26 18:40","pubTimestamp":1764153634,"startTime":"0","endTime":"0","summary":"智通财经APP讯，博雅生物(300294.SZ)公告，公司收到国家药品监督管理局签发的破伤风人免疫球蛋白《药品注册证书》。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1373993.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":"博雅生物(300294.SZ)取得破伤风人免疫球蛋白药品注册证书","news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK0046","BK0197","BK0239","300294"],"gpt_icon":0},{"id":"2586423252","title":"博雅生物：公司2025年11月20日含信用账户合并名册的股东人数为30,507户","url":"https://stock-news.laohu8.com/highlight/detail?id=2586423252","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2586423252?lang=zh_cn&edition=full","pubTime":"2025-11-25 17:03","pubTimestamp":1764061394,"startTime":"0","endTime":"0","summary":"证券之星消息，博雅生物(300294)11月25日在投资者关系平台上答复投资者关心的问题。投资者提问：公司截止今天的股东人数是多少？博雅生物回复：您好，感谢您对本公司的关注。公司2025年11月20日含信用账户合并名册的股东人数为30,507户。以上内容为证券之星据公开信息整理，由AI算法生成（网信算备310104345710301240019号），不构成投资建议。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025112500024774.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["300294","BK0197","BK0239","BK0046"],"gpt_icon":0},{"id":"2584133224","title":"博雅生物：截至目前公司未有股份回购的计划","url":"https://stock-news.laohu8.com/highlight/detail?id=2584133224","media":"证券日报 ","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2584133224?lang=zh_cn&edition=full","pubTime":"2025-11-20 18:39","pubTimestamp":1763635140,"startTime":"0","endTime":"0","summary":"证券日报网讯博雅生物11月20日在互动平台回答投资者提问时表示，公司股票价格受宏观环境、行业政策、投资者风险偏好等诸多因素影响。公司一直努力经营，提升盈利能力，实施稳健的分红政策，积极回报股东。截至目前，公司未有股份回购的计划。（文章来源：证券日报）\n\n\n海量资讯、精准解读，尽在新浪财经APP","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"sina","url":"https://finance.sina.com.cn/stock/relnews/cn/2025-11-20/doc-infxzzsw2133877.shtml","rn_cache_url":null,"customStyle":"body{padding-top:10px;}.art_tit_h1{#titleStyle#}a{#lv2TextColor#}.art_time, .art_cite{#sourceStyle#;} .art_cite{margin-left: 3px;}","selectors":".module-article, article","filters":"header, .voice2, .tags, #norm_qrcode_link_auto, .unfold-box, .action","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.sina.com.cn/stock/relnews/cn/2025-11-20/doc-infxzzsw2133877.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-2","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"sina","symbols":["BK0239","300294","BK0046","BK0197"],"gpt_icon":0},{"id":"2584693532","title":"股市必读：博雅生物（300294）11月14日董秘有最新回复","url":"https://stock-news.laohu8.com/highlight/detail?id=2584693532","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2584693532?lang=zh_cn&edition=full","pubTime":"2025-11-17 02:58","pubTimestamp":1763319489,"startTime":"0","endTime":"0","summary":"截至2025年11月14日收盘，博雅生物报收于25.4元，下跌0.04%，换手率0.74%，成交量3.73万手，成交额9513.38万元。董秘最新回复投资者： 请问华润集团是不是放弃博雅生物了，今年股价一路下跌，到处承诺尽最大努力并入丹霞，也随着管理层的更换，变成了一句空口号。华润集团如果没有能力整合，早日转给国药或者中国生物。当日关注点来自交易信息汇总：11月14日主力资金净流出758.1万元，散户资金净流入866.42万元。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025111700001062.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0046","300294","BK0239","BK0197"],"gpt_icon":0},{"id":"2583711576","title":"博雅生物：血液制品产业具有重要战略地位","url":"https://stock-news.laohu8.com/highlight/detail?id=2583711576","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2583711576?lang=zh_cn&edition=full","pubTime":"2025-11-14 17:12","pubTimestamp":1763111528,"startTime":"0","endTime":"0","summary":"证券之星消息，博雅生物11月14日在投资者关系平台上答复投资者关心的问题。血液制品在临床救治、战地救护、抗震救灾及重大传染性疾病防治中发挥着关键作用，是关系国计民生、经济发展和国家安全的战略性产业，是健康中国建设的重要基础。血液制品产业契合华润集团“1246”模式中“大国民生”和“大国重器”两大重点业务发展方向，具有重要的战略地位。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025111400027139.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0239","BK0197","300294","BK0046"],"gpt_icon":0},{"id":"2583599915","title":"博雅生物（300294）披露2025年第二次临时股东大会法律意见书，11月13日股价下跌0.2%","url":"https://stock-news.laohu8.com/highlight/detail?id=2583599915","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2583599915?lang=zh_cn&edition=full","pubTime":"2025-11-13 22:32","pubTimestamp":1763044344,"startTime":"0","endTime":"0","summary":"截至2025年11月13日收盘，博雅生物报收于25.41元，较前一交易日下跌0.2%，最新总市值为128.13亿元。该股当日开盘25.48元，最高25.5元，最低25.25元，成交额达8945.26万元，换手率为0.7%。公司近日发布公告，北京大成律师事务所就华润博雅生物制药集团股份有限公司2025年第二次临时股东大会出具了法律意见书。公告显示，本次股东大会于2025年11月13日召开，会议审议通过了关于修订公司章程及其附件、议事规则、募集资金管理制度等多项议案。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025111300042442.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0046","300294","BK0239","BK0197"],"gpt_icon":0},{"id":"2583854715","title":"股市必读：博雅生物（300294）11月12日董秘有最新回复","url":"https://stock-news.laohu8.com/highlight/detail?id=2583854715","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2583854715?lang=zh_cn&edition=full","pubTime":"2025-11-13 05:39","pubTimestamp":1762983556,"startTime":"0","endTime":"0","summary":"截至2025年11月12日收盘，博雅生物报收于25.46元，上涨0.04%，换手率0.71%，成交量3.59万手，成交额9155.23万元。董秘最新回复投资者： 请问，智能工厂计划什么时候竣工投产？公司2025年11月10日含信用账户合并名册的股东人数为30,762户。交易信息汇总资金流向11月12日主力资金净流入21.46万元；游资资金净流入247.1万元；散户资金净流出268.57万元。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025111300005347.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0197","BK0046","300294","BK0239"],"gpt_icon":0},{"id":"2582376916","title":"博雅生物：智能工厂建设正按计划推进","url":"https://stock-news.laohu8.com/highlight/detail?id=2582376916","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2582376916?lang=zh_cn&edition=full","pubTime":"2025-11-12 20:33","pubTimestamp":1762950791,"startTime":"0","endTime":"0","summary":"证券之星消息，博雅生物(300294)11月12日在投资者关系平台上答复投资者关心的问题。投资者提问：智能工厂建设进展情况，何时投入生产。如何解决目前血浆量不足以覆盖产能的问题？博雅生物回复：您好，感谢您对本公司的关注。公司智能工厂项目建设正按计划推进。公司始终坚持“内生稳增长、外延扩规模”的两步走方针，持续做好存量浆站采浆人效挖潜、新设浆站浆量爬升来统筹开展浆量提升工作；同时抓住浆站新设机会，全力申请新设浆站。以上内容为证券之星据公开信息整理，由AI算法生成（网信算备310104345710301240019号），不构成投资建议。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025111200038086.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0046","BK0239","300294","BK0197"],"gpt_icon":0},{"id":"2582376912","title":"博雅生物：智能工厂项目建设正按计划推进","url":"https://stock-news.laohu8.com/highlight/detail?id=2582376912","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2582376912?lang=zh_cn&edition=full","pubTime":"2025-11-12 20:33","pubTimestamp":1762950790,"startTime":"0","endTime":"0","summary":"证券之星消息，博雅生物(300294)11月12日在投资者关系平台上答复投资者关心的问题。投资者提问：请问，智能工厂计划什么时候竣工投产？目前浆站能否满足智能工厂投产后的供应需求？谢谢！博雅生物回复：您好，感谢您对本公司的关注。公司智能工厂项目建设正按计划推进。公司始终坚持“内生稳增长、外延扩规模”的两步走方针，持续做好存量浆站采浆人效挖潜、新设浆站浆量爬升来统筹开展浆量提升工作；同时抓住浆站新设机会，全力申请新设浆站。以上内容为证券之星据公开信息整理，由AI算法生成（网信算备310104345710301240019号），不构成投资建议。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025111200038085.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0239","BK0046","300294","BK0197"],"gpt_icon":0},{"id":"2582908367","title":"博雅生物（300294）披露变更签字注册会计师公告，11月11日股价下跌0.12%","url":"https://stock-news.laohu8.com/highlight/detail?id=2582908367","media":"证券之星","labels":["executive"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2582908367?lang=zh_cn&edition=full","pubTime":"2025-11-11 22:29","pubTimestamp":1762871360,"startTime":"0","endTime":"0","summary":"截至2025年11月11日收盘，博雅生物报收于25.45元，较前一交易日下跌0.12%，最新总市值为128.33亿元。该股当日开盘25.41元，最高25.52元，最低25.35元，成交额达7902.75万元，换手率为0.62%。公司近日发布公告称，因工作调整，公司2025年度审计项目合伙人、签字注册会计师及质量控制复核人发生变更。变更不影响审计工作的连续性，原签字会计师将继续履行保密义务。公司已收到毕马威华振出具的变更函。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025111100040960.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0046","300294","BK0239","BK0197"],"gpt_icon":0},{"id":"2582382214","title":"博雅生物（300294）股东深圳市高特佳投资集团有限公司质押53.45万股，占总股本0.11%","url":"https://stock-news.laohu8.com/highlight/detail?id=2582382214","media":"证券之星","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2582382214?lang=zh_cn&edition=full","pubTime":"2025-11-10 18:28","pubTimestamp":1762770507,"startTime":"0","endTime":"0","summary":"证券之星消息，博雅生物11月10日公开信息显示，股东深圳市高特佳投资集团有限公司向苏州诚河清洁设备有限公司合计质押53.45万股，占总股本0.11%。博雅生物主营业务：公司业务以血液制品为主,生化药、化学药为辅。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025111000027116.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0239","BK0046","300294","BK0197"],"gpt_icon":0},{"id":"2582818811","title":"股市必读：博雅生物(300294)股东户数3.08万户，较上期增加1.98%","url":"https://stock-news.laohu8.com/highlight/detail?id=2582818811","media":"证券之星","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2582818811?lang=zh_cn&edition=full","pubTime":"2025-11-10 01:35","pubTimestamp":1762709710,"startTime":"0","endTime":"0","summary":"截至2025年11月7日收盘，博雅生物报收于25.25元，上涨0.32%，换手率0.69%，成交量3.46万手，成交额8730.15万元。股本股东变化股东户数变动近日博雅生物披露，截至2025年10月31日公司股东户数为3.08万户，较9月30日增加597.0户，增幅为1.98%。户均持股数量由上期的1.67万股减少至1.64万股，户均持股市值为41.35万元。董秘最新回复投资者： 请问，截至10月31日，公司股东户数多少？公司2025年10月31日含信用账户合并名册的股东人数为30,801户。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025111000000619.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0046","BK0239","300294","BK0197"],"gpt_icon":0}],"profile":{"ret":0,"serverTime":1766038251170,"stockEarnings":[{"period":"1week","weight":-0.0222},{"period":"1month","weight":-0.0847},{"period":"3month","weight":-0.0908},{"period":"6month","weight":-0.0997},{"period":"1year","weight":-0.2449},{"period":"ytd","weight":-0.2345}],"compareEarnings":[{"period":"1week","weight":-0.0077},{"period":"1month","weight":-0.0256},{"period":"3month","weight":0.0101},{"period":"6month","weight":0.1519},{"period":"1year","weight":0.1514},{"period":"ytd","weight":0.1547}],"compareStock":{"symbol":"000001.SH","name":"上证指数"},"companyName":"华润博雅生物制药集团股份有限公司","boardCode":"AI0027","boardName":"医药制造业","stockholders":"30129人(较上一季度增加0.45%)","perCapita":"16736股","listingDate":"2012-03-08","address":"江西省抚州市临川区高新技术产业开发区惠泉路333号","registeredCapital":"50424万元","survey":"　　华润博雅生物制药集团股份有限公司的主营业务是血液制品的研发、生产和销售。公司的主要产品是白蛋白、免疫球蛋白和凝血因子。公司先后承担了国家“863计划”项目、江西省重大研发专项等20多项政府专项，拥有各类专利200余项，多次荣膺省、市科学技术奖和优秀新产品奖。","listedPrice":25},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"deviceId":"web-server-community-laohu8-v3","version":"4.35.12","shortVersion":"4.35.12","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"博雅生物(300294)_个股概要_股票价格_最新资讯_行情走势_历史数据","description":"美港股上老虎。老虎社区提供博雅生物(300294)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","keywords":"博雅生物,300294,博雅生物股票,博雅生物股票老虎,博雅生物股票老虎国际,博雅生物行情,博雅生物股票行情,博雅生物股价,博雅生物股市,博雅生物股票价格,博雅生物股票交易,博雅生物股票购买,博雅生物股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"博雅生物(300294)_个股概要_股票价格_最新资讯_行情走势_历史数据","og_description":"美港股上老虎。老虎社区提供博雅生物(300294)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","og_image":"https://static.tigerbbs.com/a0b84b8debbbce3b4440f7fdd5eed2e7"}}}